Lv3
320 积分 2023-12-02 加入
Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease
7小时前
已完结
Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID
19天前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
3个月前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
3个月前
已关闭
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry
5个月前
已关闭
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
7个月前
已完结
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
8个月前
已完结
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA
10个月前
已完结
The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes
1年前
已完结
皖公网安备34019202002308
